mRNA technology Archives

News and Trends 21 Dec 2022

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

ExPLoRNA Therapeutics receives mRNA technology funding

ExPLoRNA Therapeutics, a Polish biotech company working on mRNA vaccines and therapeutics, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA crucial for enabling successful production of the encoded protein. ExPLoRNA’s technology increases protein production beyond the […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

AI works on artificial DNA for future drug development

With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs […]

November 24, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

BIA and Exopharm sign joint research agreement to develop integrated technology

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

November 23, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Nov 2022

Agreement boosts mRNA manufacturing in Singapore

RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company, and the Agency for Science, Technology and Research (A*STAR) have signed a research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore. RVAC and A*STAR will set up a joint laboratory based at A*STAR’s Bioprocessing Technology […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Novel branched lipid boosts mRNA delivery to cells

A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming

Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). Direct reprogramming is the direct conversion of the fate of cells without passing through the pluripotent state. This agreement expands the scope of the technology evaluation agreement for […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy

The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering

Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us